Bendamustine

Drug Profile

Bendamustine

Alternative Names: BENDA; Bendam; Bendamus; Bendamustine HCl; Bendamustine hydrochloride; Bentaman; Cytostasan; Endexin; Esevaril; Innomustine; Levact; Ribomustin; Ribomustine; Ribovact; SDX-105; SyB L-0501; Symbenda; Treakisym; Treanda

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astellas Pharma GmbH
  • Developer Astellas Pharma GmbH; Cantonal Hospital of St Gallen; Eisai Co Ltd; Foundation GIMEMA; GlaxoSmithKline KK; INNOPHARMAX; Istituto Clinico Humanitas; Janssen-Cilag; Memorial Sloan-Kettering Cancer Center; Mundipharma International; Northside Hospital; PETHEMA Foundation; St. Jude Childrens Research Hospital; SymBio Pharmaceuticals; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Cancer; Chronic lymphocytic leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase II MALT lymphoma
  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Discontinued Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 10 Apr 2017 Genentech plans a phase II trial for Follicular lymphoma (First-line therapy, Combination therapy, Late-stage disease) (NCT03113422)
  • 01 Feb 2017 Millennium Pharmaceutical completes a phase II trial in Multiple myeloma (First-line therapy, Combination therapy) in USA (IV) (NCT01056276)
  • 31 Jan 2017 First generic equivalent approved in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top